MGTA insider filings
Magenta Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-02-09. Screen MGTA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for MGTA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Magenta Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-02-09 | 4 | Third Rock Ventures IV, L.P. — 10% owner Third Rock Ventures GP IV, L.P. — 10% owner TRV GP IV, LLC — 10% owner | Sale (S): 2,200,000 @ $0.83 · Sale (S): 1,500,000 @ $0.82 | EDGAR |
| 2022-12-02 | 4 | Beetham Thomas W. — See Remarks | Grant/award (A): 3,000 @ $0.94 | EDGAR |
| 2022-12-02 | 4 | Mahoney Stephen F. — See Remarks | Grant/award (A): 3,000 @ $0.94 | EDGAR |
| 2022-12-02 | 4 | Deardorf Caren — Chief Commercial Officer | Grant/award (A): 3,000 @ $0.94 | EDGAR |
| 2022-12-02 | 4 | GARDNER JASON — See Remarks, Director | Grant/award (A): 3,000 @ $0.94 | EDGAR |
| 2022-12-02 | 4 | Stants Kristen — Chief People Officer | Grant/award (A): 3,000 @ $0.94 | EDGAR |
| 2022-08-17 | 4 | VASCONCELLES MICHAEL — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Olson Lisa — See Remarks | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Beetham Thomas W. — See Remarks | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Humphrey Jeffrey — Chief Medical Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | GARDNER JASON — See Remarks, Director | Grant/award (A): 187,500 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Nichols David Wayne — Chief Technical Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Mahoney Stephen F. — See Remarks | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Stants Kristen — Chief People Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Deardorf Caren — Chief Commercial Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | Scadden David — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | McGeorge Anne — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | Albers Jeffrey W. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | Lawton Alison Frances — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | Daniel Thomas O — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | Booth Bruce — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-30 | 4 | RONNEBERG AMY L — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | Stants Kristen — Chief People Officer | Grant/award (A): 3,000 @ $0.99 | EDGAR |
| 2022-06-06 | 4 | Deardorf Caren — Chief Commercial Officer | Grant/award (A): 3,000 @ $0.99 | EDGAR |
| 2022-06-06 | 4 | GARDNER JASON — See Remarks, Director | Grant/award (A): 3,000 @ $0.99 | EDGAR |
| 2022-06-06 | 4 | Beetham Thomas W. — See Remarks | Grant/award (A): 3,000 @ $0.99 | EDGAR |
| 2022-05-19 | 4 | Olson Lisa — See Remarks | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Humphrey Jeffrey — Chief Medical Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | GARDNER JASON — See Remarks, Director | Grant/award (A): 162,500 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Stants Kristen — Chief People Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Nichols David Wayne — Chief Technical Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Mahoney Stephen F. — See Remarks | Grant/award (A): 62,500 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Beetham Thomas W. — See Remarks | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Deardorf Caren — Chief Commercial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | GARDNER JASON — See Remarks, Director | Grant/award (A): 187,500 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | Humphrey Jeffrey — Chief Medical Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | Deardorf Caren — Chief Commercial Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | Stants Kristen — Chief People Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | Nichols David Wayne — Chief Technical Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | Olson Lisa — See Remarks | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | Mahoney Stephen F. — See Remarks | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2022-02-17 | 4 | Beetham Thomas W. — See Remarks | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2021-10-04 | 4 | Humphrey Jeffrey — Chief Medical Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2021-09-23 | 4 | Borisy Alexis — Director | Other (J): 4,100 @ $0 | EDGAR |
| 2021-09-20 | 4 | Mahoney Stephen F. — See Remarks | Sale (S): 5,736 @ $6.73 | EDGAR |
| 2021-09-20 | 4 | Deardorf Caren — Chief Commercial Officer | Sale (S): 6,238 @ $6.73 | EDGAR |
| 2021-09-20 | 4 | GARDNER JASON — See Remarks | Sale (S): 14,340 @ $6.73 | EDGAR |
| 2021-09-20 | 4 | Beetham Thomas W. — See Remarks | Sale (S): 6,103 @ $6.73 | EDGAR |
| 2021-09-20 | 4 | Olson Lisa — See Remarks | Sale (S): 5,736 @ $6.73 | EDGAR |
| 2021-09-20 | 4 | Nichols David Wayne — Chief Technical Officer | Sale (S): 5,694 @ $6.73 | EDGAR |
Recent 8-K events — Magenta Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MGTA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs